Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2013

Chatterjee R, Hoffman M, Cliften P, Seshan S, Liapis H, Jain S. Targeted exome sequencing integrated with clinicopathological information reveals novel and rare mutations in atypical, suspected and unknown cases of Alport syndrome or proteinuria. PLoS One. 2013;8(10):e76360.

Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, et al. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013;2:e43.

Lin P-, Chiu Y-, Banerjee S, Park K, Mosquera JM, Giannopoulou E, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013;73(3):1232-44.

M Seibenhener L, Du Y, Diaz-Meco M-, Moscat J, Wooten MC, Wooten MW. A role for sequestosome 1/p62 in mitochondrial dynamics, import and genome integrity. Biochim Biophys Acta. 2013;1833(3):452-9.

Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica. 2013;98(4):635-9.

Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Leurgans SE, Yu L, et al. Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study. Neuroepidemiology. 2013;40(2):73-84.

Iglesias-Ussel M, Vandergeeten C, Marchionni L, Chomont N, Romerio F. High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol. 2013;87(16):9148-58.

Marchionni L, Afsari B, Geman D, Leek JT. A simple and reproducible breast cancer prognostic test. BMC Genomics. 2013;14:336.

D'Alfonso TM, Scognamiglio T. Myofibroblastoma with chondroid metaplasia. Breast J. 2013;19(5):549-51.

Kleiman DA, Sporn MJ, Beninato T, Crowley MJ, Nguyen A, Uccelli A, et al. Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. Cancer. 2013;119(8):1495-502.